In our previous study, 14 sulfated carbohydrate tumor marker candidates were identified by focused glycomic analyses. Here, glycomic analyses focused on internally sialylated glycans to identify novel marker candidates. Internally sialylated glycans were enriched by digestion of pyridylaminated glycans prepared from sera with α-neuraminidase from Salmonella typhimurium, which did not cleave sialic acids linked to internal residues, followed by anion-exchange chromatography. Next, internally sialylated O-glycan profiles were constructed using two types of high performance liquid chromatography, which were compared between 20 healthy controls and 11 patients with gastric cancer and 9 patients with pancreatic cancer. In all, 17 marker candidates were identified. The structures of glycan candidates were precisely analyzed using enzymatic digestion, glycan synthesis, 2D mapping and mass spectrometry. Among 17 candidates, one was STn, and the other 16 comprised 10 core1, 1 core2 and 5 core3 glycans. The various structures included a α2,6-sialylated reducing terminal GalNAc and α2,6-sialylated type1 N-acetyl-lactosamine. Eight candidates possessed the Sd a /CAD antigen. The levels of these candidate glycans in sera from all 40 subjects were quantified using a selected reaction monitoring assay and found to be elevated in at least one or more patients. Although the serum levels of each candidate glycan varied between patients, those candidates having the same backbone or determinant, such as core3 backbone and core1 structures with extended type1 N-acetyl-lactosamine, displayed similar patterns of elevation. These results suggest that analysis of multiple markers may be an effective means of diagnosing various cancers.
Introduction
One of the most well-known cancerous phenotypes in tumor cells is aberrant glycosylation (Pinho and Reis 2015) . Aberrant carbohydrate structures, like the immature truncated form of O-glycan, sialyl Tn antigen (STn), and de novo expressed carbohydrate determinants, sialyl Lewis A (SLe a ) and sialyl Lewis X (SLe x ), are valuable markers for cancer diagnosis (Del Villano et al. 1983; Chia et al. 1985; Kannagi et al. 1986 Kannagi et al. , 1988 Motoo et al. 1991) . However, despite the application of various serological biomarkers for clinical diagnosis of cancer, they are not always effective. Thus, there is an urgent need to identify novel tumor markers that are more reliable predictors of cancer. Recently, serum glycomics and glycoproteomics studies have been extensively performed to identify novel glycan biomarkers for a variety of cancers, primarily using newly developed high-throughput platform technologies, such as mass spectrometry-based methods and lectin-based methods (Okuyama et al. 2006; Kirmiz et al. 2007; Abd Hamid et al. 2008; Jung et al. 2009; Abbott et al. 2010; Alley et al. 2010 Alley et al. , 2012 Arnold et al. 2011; de Leoz et al. 2011; Adamczyk et al. 2012; Biskup et al. 2013; Hua et al. 2013; Kaji et al. 2013; Gbormittah et al. 2014; Pan et al. 2014; Hamfjord et al. 2015) .
We have attempted to identify novel carbohydrate tumor markers from human sera using high performance liquid chromatography (HPLC)-based methods. One approach was to treat serum glycoproteins from cancer patients or healthy controls with hydrazine and label the liberated glycans with a fluorophore, 2-aminopyridine (2-AP). The pyridylaminated (PA)-glycan mixtures were then separated by normal phase HPLC followed by reversed phase HPLC. The fluorescence intensities of the corresponding peaks on the second chromatograms were then precisely compared between sera taken from cancer patients and healthy controls. Cancer-specific peaks were recognized as tumor marker candidates. Tumor marker oligosaccharide antigens in clinical use are thought to be carried on the mucin-type O-glycans (Magnani et al. 1983; Lan et al. 1985; Lloyd et al. 1997 ). Thus, we focused exclusively on O-linked oligosaccharides as the target for the markers. Using this HPLC-based method, several O-glycan candidates were successfully identified (Tanaka-Okamoto et al. 2016) . One of these candidate glycans included a core1 sialyl Lewis A structure, C1SLA, a CA19-9 related glycan. These results indicated that the HPLC-based procedure used in our study was an effective means of identifying novel glycan marker candidates. Nonetheless, during analyses of our original HPLC-based approach we recognized a potential problem with the methodology. Sulfated oligosaccharides, which are minor components, are thought to be strong candidates for tumor markers Karlsson and McGuckin 2012) . However, in human sera, the majority of serum oligosaccharides, more than 99%, are composed of neutral glycans or terminally sialylated acidic glycans (i.e., sialic acid linked to the nonreducing terminus) (Yabu et al. 2014) . Therefore, using our original HPLC-based method, minor components, such as sulfated glycans, could easily be overlooked due to overlapping peaks derived from the major glycans. In order to resolve this issue, we performed glycomic analyses focused on sulfated glycans with α-neuraminidase from Arthrobacter ureafaciens, which liberates all the N-acetylneuraminic acid (NeuAc) residues regardless of linkage position (α2,3, α2,6 and α2,8) . Adopting this approach facilitated the identification of 14 sulfated carbohydrate tumor marker candidates (Tanaka-Okamoto et al. 2017) . These results revealed focused glycomics to be a powerful tool in the search for novel tumor biomarkers, even when present as very minor components in sera.
Next, we carried out focused glycomics to identify additional tumor markers. Here, we targeted internally sialylated determinants, which include oligosaccharides having α2,6-sialylated type1 Nacetyl-lactosamine (LacNAc), (i.e., sialic acid attached to the N-acetylglucosamine residue of Galβ1-3GlcNAc-moiety via α2,6-linkage (Galβ1-3(NeuAcα2-6)GlcNAc-R)) and core 1 and core 3 structures having α2,6-sialylated N-acetylgalactosamine (R 1 -(NeuAcα2-6)GalNAc-R 2 ). Although internally sialylated oligosaccharides comprise a very minor component of sera, they are thought to be potential tumor markers (i.e. akin to sulfated glycans). Specifically, disialosyl Lewis A determinant, (NeuAcα2-3Galβ1-3(NeuAcα2-6)(Fucα1-4) GlcNAc-R) was recognized as a cancer-specific antigen (Nudelman et al. 1986 ). Additionally, the presence of a disialosylated Lewis C structure (NeuAcα2-3Galβ1-3(NeuAcα2-6)GlcNAc-R) was also reported in human embryonic carcinoma cells . In this study, we performed glycomic analysis focusing on internally sialylated oligosaccharides. To enrich for internally sialylated oligosaccharides, we utilized the substrate specificity of α-neuraminidase from Salmonella typhimurium. Unlike α-neuraminidase from A. ureafaciens, which is used to enrich for sulfated glycans, α-neuraminidase from S. typhimurium can remove sialic acid linked to the nonreducing terminal ends via both α2,3-and α2,6-linkages, but not the sialic acids linked to internal residues (e.g. subterminal and the reducing terminal) under the conditions used in this study (see Materials and methods). Dose-dependent substrate specificity of this neuraminidase was clearly demonstrated in our previous study (Korekane et al. 2007; Shida et al. 2009 ). Upon digestion with α-neuraminidase from S. typhimurium, terminally sialylated acidic oligosaccharides were transformed to neutral oligosaccharides. However, this was not the case for acidic oligosaccharides, such as internally sialylated glycans and sulfated glycans, which were neuraminidase resistant. When PA-glycan mixtures that had been treated with S. typhimurium neuraminidase were subjected to weak anion exchange chromatography, neutral glycans and terminally sialylated acidic oligosaccharides, which comprise the vast majority of serum glycans, eluted at the position corresponding to neutral glycans. However, internally sialylated and sulfated oligosaccharides eluted and enriched in the acidic fraction.
In this study, glycomics analyses focused on internally sialylated oligosaccharides using serum samples from 20 healthy controls and 20 adenocarcinoma patients with gastric and pancreatic cancers enabled us to identify 17 internally sialylated carbohydrate marker candidates. The precise structures of these candidate glycans were also elucidated. Furthermore, the levels of these internally sialylated candidates in sera from all 40 individuals were quantified using selected reaction monitoring (SRM) analyses and their potential utility for clinical application evaluated.
Results
Enrichment of internally sialylated PA-glycans by utilizing the substrate specificity of α-neuraminidase Serum PA-glycans from 20 healthy controls, 11 gastric cancer patients and 9 pancreatic cancer patients were prepared as previously reported (Tanaka-Okamoto et al. 2017) . Sera samples were numbered G1-G11 for gastric cancer patients and P1-P9 for pancreatic cancer patients. The clinical features of the 20 patients are summarized in Supplementary Table SI. These 20 cancer patients were the same as those analyzed in our previous study regarding sulfated marker candidates (Tanaka-Okamoto et al. 2017) .
To enrich for internally sialylated oligosaccharides, PA-glycan mixtures derived from 20 μl of serum were digested with α-neuraminidase from S. typhimurium, and then the samples were subjected to DEAE anion exchange chromatography (Figure 1 ). Figure 1 , line A NA (−), shows the elution profile for DEAE anion exchange chromatography of PA-glycans prior to α-neuraminidase digestion. The profile consists of one major peak in the neutral region (N), three major peaks in the acidic A1-A2 region and three minor peaks in the acidic A3 region. Figure 1 , line B NA (+), shows the corresponding elution profile for DEAE anion exchange chromatography of PA-glycan mixtures digested with α-neuraminidase from S. typhimurium. In contrast to the undigested PA-glycans, almost all the neuraminidase digested glycans eluted at the neutral position. This major peak in the neutral fraction was composed of the original neutral glycans and terminally sialylated glycans that were neutralized after digestion. Two very minor peaks were observed in the A1 fraction (indicated by asterisks). The bulk of glycans in the early peaks (before 10 min) were not PA-glycans, which represented only a minor component. The late peak (after 10 min) was derived from Galβ1-3(NeuAcα2-6)GalNAc-PA, which is the only major serum acidic glycan resistant to α-neuraminidase from S. typhimurium. Minor peaks were also evident in the A2-A4 acidic fractions when the chromatogram was enlarged (see enlarged view of acidic area). These acidic fractions were separately collected in the A1 range (7.5-10 min) and A2-A4 range (10-20 min), which include both internally sialylated and sulfated glycans as major components.
Construction and comparison of internally sialylated PA-glycan profiles
Following separation by DEAE ion exchange chromatography, the acidic fractions (A1 and A2-4) were subjected to normal phase HPLC. During normal phase HPLC, most O-linked glycans elute within the first 50 min whereas N-linked glycans elute after 50 min (Yabu et al. 2014) . O-linked oligosaccharides that eluted between 8 and 55 min in normal phase HPLC from the A1 and A2-4 range were divided into six and eight fractions, respectively (Supplementary Figure S1 ). Each fraction was further separated by reversed phase HPLC. The HPLC chromatograms obtained from healthy controls and cancer patients were then compared to identify marker candidate peaks, as previously described (Figure 2 ) (Tanaka-Okamoto et al. 2017) . These candidate peaks were defined as either (1) peaks present in samples from cancer patients but absent from those derived from the healthy controls, or (2) peaks found in samples from cancer patients that are significantly elevated compared to the corresponding peaks from normal controls. As expected, all the marker candidate peaks derived from sulfated oligosaccharides that had been previously reported were detected (Tanaka-Okamoto et al. 2017) . In addition to peaks from sulfated candidates, 14 other peaks from the A1 range and three peaks from the A2-4 range were also found (highlighted by dotted arrows) (Figure 2 ). The candidate PA-glycans were numbered according to their glycan structure, as listed in Tables I and II . The peaks derived from sulfated compounds that have been previously reported are highlighted by asterisks in Figure 2 . Elevated levels of candidate peaks were observed in sera from G2, G8 and P3. All candidate peaks were subjected to MS/MS analysis.
Structural analyses of candidate glycans by mass spectrometry
The collected candidate peaks were further analyzed by mass spectrometry. Careful examination of MS 2 spectra revealed that all of the 17 candidates were internally sialylated oligosaccharides. The mass spectrometry data enabled the composition and structures of the candidate glycans to be estimated (refer to Table I ). The precursor ions in MS and product ions in MS 2 are protonated ions, [M + H] + . Analysis using MS showed peak No. 1 corresponds to STn. Peak Nos. 9, 11, 15, 16 and 17 appeared to be peeling products of core1 glycan, lacking a GalNAc residue at the reducing terminal end (Table I ). We previously reported that O-glycans having extended core1 structures (longer than four glycans) without sialylation at the reducing terminal ends are highly susceptible to base catalyzed β-elimination (peeling) and most of them lack a reducing terminal GalNAc (Tanaka-Okamoto et al. 2016) . The structures of peak Nos. 15 and 17 could not be determined, either as branched or straight chain oligosaccharides, by MS analyses. Surprisingly, eight candidate carbohydrates (Nos. 5, 6, 7, 8, 9, 10, 11 and 12) . The classification of core structures for each candidate is described in detail in the following section.
Precise structural analyses of candidate glycans
The structures of internally sialylated carbohydrates were precisely analyzed using a combination of 2D mapping, enzymatic digestion and mass spectrometry, together with synthesis of new oligosaccharides using glycosyltransferases. The quantities of these candidate glycans obtained from sera samples was too small for precise structural Figure 1 . Enrichment of internally sialylated PA-glycans using digestion of PAglycan mixtures with α-neuraminidase from S. typhimurium (NA) followed by separation on a DEAE anion exchange column. (A) Elution profile from DEAE anion exchange chromatography of PA-glycan mixtures that were not treated with α-neuraminidase (NA(−)). PA-glycan mixtures prepared from human sera were separated into neutral (N) and acidic (A1-A4) fractions. Arrowheads labeled N and A1-A4 indicate elution positions of standard neutral PA-glycans and standard PA-glycans with 1-4 sialic acids, respectively. (B) Elution profile from DEAE anion exchange chromatography of PA-glycan mixtures digested with α-neuraminidase from S. typhimurium (NA(+)). One major peak was observed at the neutral position. The two thick bars indicate the collected fractions, A1 and A2-4 ranges. Enlarged view of the collected area is shown inset above the original line. Asterisks highlight two minor peaks in the collected area. The majority of peaks before 10 min were not PA-glycans, which represent only minor components. The peak after 10 min was derived from Galβ1-3(NeuAcα2-6)GalNAc-PA. Chromatogram of G2 patient was representatively shown in Figure 1 . There was no difference between the elution profiles for DEAE anion exchange chromatography of PA-glycans from cancer patients and normal controls.
determination. Therefore, in addition to the patient sera samples, various alternative samples were also used as a source of candidate glycans, including cancer, adenoma and normal tissues from pancreas and colon. Nos. 1 and 2 were judged to be STn (NeuAcα2-6GalNAc) and sialyl core3 (GlcNAcβ1-3(NeuAcα2-6)GalNAc), respectively, because they were identical to authentic compounds on a map constructed from standard PA-glycans ( Figure 3A ). In agreement with many previous reports, STn antigen (No. 1) was detected as a tumor marker candidate in the glycomics procedure, suggesting that our screening approach was effective. In addition to STn and sialyl core3, some standard PA-O-glycans were used as reference compounds for structural analyses. These standard PA-O-glycans included type2-core3 structure; Galβ1-4GlcNAcβ1-3GalNAc-PA, Galβ1-3(NeuAcα2-6)GalNAc-PA, β1-6 arm structure; Galβ1-4GlcNAcβ1-6Gal-PA, type1-and type2-core1 basal structures; Galβ1-3GlcNAcβ1-3Gal-PA and Galβ1-4GlcNAcβ1-3Gal-PA, type2 LacNAc; Galβ1-4GlcNAc-PA, Galβ1-3GalNAc-PA and core 2 basal structures; Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAc-PA. The series of analytical approaches employed in these structural analyses are illustrated in Figure 3 .
Core3 candidates, Nos. 3 and 4, had NeuAc α2,6-linked to a reducing terminal GalNAc ( Figure 3B ). The product of No. 3 digested with α-neuraminidase from A. ureafaciens (abbreviated as S in Figure 3 ) was identical to type2-core3 standard Galβ1-4GlcNAcβ1-3GalNAc-PA. Moreover, digestion of monofucosylated No. 4 with α1,3/4-fucosidase (34F in Figure 3 ) resulted in conversion to No. 3 ( Figure 3B ).
In core1 candidates, Nos. 13 and 14 also had NeuAc α2,6-linked to a reducing terminal GalNAc ( Figure 3C ). The digestion product of No. 14 with α1,3/4-fucosidase ran on the 2D map at the same position as No. 13. Lacto-N-biosidase (Bio in Figure 3 ) digestion of No. 13 released one type1 LacNAc unit and its digestion product corresponded to reference compound Galβ1-3(NeuAcα2-6)GalNAc-PA on the 2D map. Thus, the backbone structure of Nos. 13 and 14 was type1 LacNAc-extended core1 (Galβ1-3GlcNAcβ1-3Galβ1-3GalNAc) ( Figure 3C ).
Nos. 15, 16 and 17 candidates had type1 LacNAc moiety with sialic acid linked to the subterminal GlcNAc ( Figure 3D and E). The backbone structure of No. 16 and No. 15 were a straight chain core1 structure extended by one type1 LacNAc unit (Galβ1-3GlcNAcβ1-3Gal) and two type1 LacNAc units (Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Gal), respectively, as detailed below. The backbone structure of No. 17 was a type1/type2 LacNAc hybrid branched core1 structure, with the former and latter linked to the C3 and C6 position of galactose, Galβ1-4GlcNAcβ1-6(Galβ1-3GlcNAcβ1-3)Gal. No. 15 was digested with α-neuraminidase from A. ureafaciens. Figure 3 ) was resistant to β-N-acetylhexosaminidase (Hex in Figure 3 ), which is capable of cleaving β-linked HexNAc but not that with sialic acid ( Figure 3D ). Thus, sialic acid appears to be linked to a subterminal GlcNAc.
No. 16 treated with α1,3/4-fucosidase and α-neuraminidase from A. ureafaciens converted to type1-core1 basal structure, Galβ1-3GlcNAcβ1-3Gal-PA. No. 17 had a branched core1 structure. The sequential digestion product of No. 17 with α-neuraminidase from A. ureafaciens and lacto-N-biosidase, followed by α1,3/4-fucosidase, resulted in a standard type2 LacNAc unit on the β1-6 arm. However, digestion of No. 17 with α1,3/4-fucosidase, β1,4-galactosidase (4G in Figure 3 ) and β-N-acetylhexosaminidase resulted in the products mapping to the same position as defucosylated No. 16 (Galβ1-3(NeuAcα2-6)GlcNAcβ1-3Gal-PA) on the 2D map ( Figure 3E ). Reversed phase HPLC chromatograms of fraction 2, 3, 4, 5 and 6 of A1 eluted range (A, B, C, D and E) and fraction 1, 5 and 7 of A2-4 eluted range (F, G and H) from three cases of normal controls (indicated by N), four cases of gastric cancer patients (G2, G3, G7 and G8) and three cases of pancreatic cancer patients (P1, P3 and P4) are shown. Asterisked peaks are sulfated marker candidate glycans that have been previously reported. Dotted arrowed lines in each Figure indicate candidate peaks that were derived from internally sialylated, but not sulfated, glycans and that displayed increased levels in cancer patients. Numbers below the dotted arrows correspond to the candidate PAglycan numbers listed in Tables I and II. The Sd a /CAD antigen was identified as the blood group (Macvie et al. 1967; Renton et al. 1967 ) and possesses a unique structure consisting of the β1,4-GalNAc residue linked to galactose with α2,3-sialic acid, GalNAcβ1-4(NeuAcα2-3)Gal-R (Blanchard et al. 1983; Donald and Feeney 1986) . As described in the section of Structural analyses of candidate glycans by mass spectrometry, among 17 internally sialylated candidates, eight carbohydrates (Nos. 5, 6, 7, 8, 9, 10, 11 and 12) were estimated to have Sd a /CAD antigens. This speculation was confirmed by the following precise structural analysis. The structure of No. 5, core3 glycan, was presumed to have an Sd a /CAD determinant on the Galβ1-4GlcNAcβ1-3GalNAc backbone ( Figure 3B ). This proposed product was newly synthesized as follows. Type2-core3 structure, Galβ1-4GlcNAcβ1-3GalNAc-PA, was prepared by digestion of No. 3 with α-neuraminidase from A. ureafaciens. The α2,3-sialylated form of type2-core3 was generated from the backbone structure of No. 3 using α2,3-sialyltransferase (23ST in Figure 3 ). High enzyme activity or RNA expression of the Sd a /CAD-β1,4-GalNAc transferase has been demonstrated in colonic tissue (Malagolini et al. 1989; Montiel et al. 2003) . Thus, a GalNAc residue was transferred to the terminal galactose via a β1,4-linkage using human normal colon lysate as an enzyme source (abbreviated as GalNT in Figure 3 ). As predicted, the synthesized product was identical to No. 5 on the map. Similarly, No. 12 was presumed to have an Sd a /CAD determinant on No. 13, Galβ1-3GlcNAcβ1-3Galβ1-3 (NeuAcα2-6)GalNAc-PA ( Figure 3C ). The structure of No. 12 was estimated based on 3′-sialylation of No. 13 followed by addition of a GalNAc residue to the terminal galactose via a β1,4-linkage. Digestion of Nos. 6, 7, 8, 9, 10 and 11 with α-neuraminidase from A. ureafaciens and β-N-acetylhexosaminidase followed by MS/MS analyses revealed that their backbone structures were standard PA-glycans; Galβ1-4GlcNAc-PA (No. 6), Galβ1-3GalNAc-PA (Nos. 7 and 8), Galβ1-4GlcNAcβ1-3Gal-PA (No. 9), Galβ1-4GlcNAcβ1-6(Galβ1-3) GalNAc-PA (No. 10) and Galβ1-3GlcNAcβ1-3Gal-PA (No. 11), respectively. Fortunately, 3′ terminally sialylated oligosaccharides of these six backbones, shown in Figure 3F (left side), had already been obtained as reference compounds from our previous study. The estimated structures are shown schematically. Symbol representations of glycans are: hexose (Hex), circle; N-acetylhexosamine (HexNAc), square; deoxyhexose (dHex), triangle; sialic acid (NeuAc), diamond.
Calculated mass was used as the Q1 transition by SRM. a Two transitions were monitored. However, only the transition shown in bold was used as the quantifier transition. The candidate glycans used for structural analyses were isolated from human cancer, adenoma, normal tissues and sera from patients. The structures of these candidates were determined by employing a combination of methods, including sequential enzymatic digestion, mass spectrometry and synthesis of Sd a /CAD carbohydrates. Each strategy is illustrated in (A) for Nos.1 and 2, (B) for Nos. 3, 4 and 5, (C) for Nos. 13, 14 and 12, (D) for No. 15, (E) for Nos. 16 and 17 and (F) for Nos. 6, 7, 8, 9, 10 and 11. Glycosidase and glycosyltransferase abbreviations are as follows: 34 F, α1,3/4-fucosidase; S, α-neuraminidase from A. ureafaciens; 3 G, β1,3-galactosidase; 4 G, β1,4-galactosidase; Bio, lacto-N-biosidase; Hex, β-N-acetylhexosaminidase; 23ST, sialylation to C3 position of galactose by α2,3-(N)-sialyltransferase and GalNT, addition of GalNAc to C4 position of galactose with α2,3-NeuAc. Symbol representations of glycans are as follows: galactose, yellow circle; GlcNAc, blue square; GalNAc, yellow square; fucose, red triangle; sialic acid (NeuAc), purple diamond. The linkage position of carbohydrate, except for GlcNAc, is indicated by the angle of the line as illustrated in the right upper box.
GalNAc residues were transferred to these sialylated standards and the synthesized products found to be identical to Nos. 6, 7, 8, 9, 10 and 11. Curiously, the reducing terminal structure of No. 6 was a type2 LacNAc, which is not a basal O-glycan structure. However, this oligosaccharide is probably a peeling product, which lacks the reducing terminal GalNAc of No. 5. Extended core3 O-glycans are degraded by hydrazine treatment and lack reducing terminal GalNAc residues, as well as an extended core1 structure. However, when the reducing end GalNAc is sialylated, extended core1 and core3 glycans are resistant to peeling (unpublished data). Thus, No. 6 was regarded as core3 O-glycan. This hypothesis was supported from the following quantification of each candidate level in sera. All the carbohydrate structures are listed in Table II .
Comparison of the levels of internally sialylated marker candidate PA-glycans in sera of healthy controls and adenocarcinoma patients quantified by SRM analyses
We identified 17 marker candidates by focused glycomics analyses using PA-O-glycans prepared from the sera of healthy controls and gastric and pancreatic cancer patients. Precise quantification of the serum levels of these glycans is essential for the preliminarily evaluation of the usefulness of each candidate. Serum levels of these candidate glycans were accurately quantified using the SRM assay as performed in our previous study (Tanaka-Okamoto et al. 2016) . Unfortunately, in this experiment, high accuracy could not be fully guaranteed because we were unable to prepare stable isotope-labeled internal standards of all candidates that are required for precise quantification. However, two kinds of internal standard for STn (No. 1) and sialyl core3 (No. 2) were prepared, and their precise levels in sera quantified. The levels of two glycans obtained by SRM quantifications using stable isotope-labeled internal standards were compatible with those from the SRM assay for relative comparison. Additionally, these SRM analyses showed reproducible results. Thus, for a preliminary evaluation, we concluded that the obtained values were reliable.
The calculated mass of [M + H]
+ for the Q1 transition and the selected mass for Q3 transitions for detection of the candidate PAglycans are listed in Table I . The peak area in the extracted ion chromatogram of each SRM transition was then measured. The serum levels of each candidate marker derived from 11 gastric cancer patients, 9 pancreatic cancer patients and 10 normal controls are shown in Figure Supplementary Table SII. ) Although the serum levels of each candidate glycan obtained by SRM analyses showed various patterns, candidates having the same backbone or determinant were present at similar levels. Thus, for clarity, the graphs are listed according to the type of pattern as described below (Figure 4B -F, G-I, J, K, L-O, P and Q). Elevated levels of all the candidate glycans in samples of at least one or more cancer patients were observed. An elevated level of truncated O-glycan, STn (No. 1) was observed in various cancer patient sera ( Figure 4A) . Figure 4B -F shows the levels of candidates having core3 backbone structures, Nos. 2, 3, 4, 5 and 6, respectively. These core3 candidates were composed of three glycans with sialic acid linked to the reducing terminal GalNAc (Nos. 2, 3 and 4) and two glycans having an Sd a / CAD determinant (Nos. 5 and 6). Regardless of their structural diversity, the levels of these five core3 candidates shared one common feature; namely, a marked elevation in sera from two cancer patients (G2 and G8). As mentioned above, No. 6 was thought to be a peeling product of No. 5. Though the level of No. 6 was an order of magnitude higher than that of No. 5, the pattern of levels in all cases was strikingly similar ( Figure 4E and F). The levels of three candidates having a α2,6-sialylated type1 LacNAc structure (Galβ1-3(NeuAcα2-6)GlcNAc-R), Nos. 15, 16 and 17, are shown in Figures 4G, H and I , respectively. The levels of these candidates were slightly elevated in several gastric and pancreatic patients. Figure 4J and K shows the levels of candidates having a short core1 basal structure, Galβ1-3GalNAc-PA, with an Sd a /CAD determinant (Nos. 7 and 8). The sera levels of these two candidates were increased in only one case (P3). The levels of candidates having a core1 structure with an extended type1 LacNAc unit, Nos. 11, 12, 13 and 14, are shown in Figure 4L , M, N and O, respectively. Among these four candidates, Nos. 11 and 12 had an Sd a /CAD determinant on the type1 LacNAc unit ( Figure 4L and M) . The levels of these four candidates, Nos. 11, 12, 13 and 14, were similar to those of candidates Nos. 7 and 8, but with a somewhat different pattern ( Figure 4J-O) . Specifically, the level of P3 of the four candidates was significantly elevated compared to those of normal controls, probably by an order of magnitude higher, whilst, those of Nos. 7 and 8 were two to three times higher than normal controls. The levels of these four candidates in normal controls were either very low (No. 11) or below the detection limit (Nos. 12, 13 and 14) . In addition to P3, increased levels of these candidates were observed in several sera from cancer patients, such as G2, G8 and P9 of No. 12 . Figure 4P and Q shows the levels of candidates, Nos. 9 and 10, respectively. The former has a core1 structure with an extended type2 LacNAc unit, and the latter has a basal core2 structure. Both these candidates had Sd a /CAD determinants. The level of No. 9 was markedly elevated in sera of G8 and P3. The level of No. 10 was increased in sera of G2, G3 and G7, in addition to G8 and P3.
Discussion
In our previous study, 14 sulfated marker candidates were identified by focused glycomic analyses using α-neuraminidase from A. ureafaciens, which can release NeuAc independent of linkage position (Tanaka-Okamoto et al. 2017) . In this study, glycomic analyses focused on internally sialylated glycans by utilizing the substrate specificity of α-neuraminidase from S. typhimurium, which can remove sialic acids linked to terminal ends but not the sialic acids linked to internal residues (Korekane et al. 2007; Shida et al. 2009 ). This approach enabled us to identify 17 internally sialylated marker candidates, in addition to sulfated candidates. These results strongly suggested that the enrichment process using α-neuraminidase digestion followed by DEAE separation was very effective at identifying marker candidates of minor components. However, digestion of the oligosaccharide with α-neuraminidase alters its original structure, i.e. cleaving the sialic acid residue linked to the nonreducing terminal is unavoidable. For example, the original structures of No. 4 (Galβ1-4(Fucα1-3) GlcNAcβ1-3(NeuAcα2-6)GalNAc-PA) and No. 17 (Galβ1-4(Fucα1-3) GlcNAcβ1-6(Galβ1-3(NeuAcα2-6)GlcNAcβ1-3)Gal-PA), and No. 14 (Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-3(NeuAcα2-6)GalNAc-PA) in sera might possess sialyl Lewis X (NeuAcα2-3Galβ1-4(Fucα1-3) GlcNAc-R) or sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAc-R) determinants. Similarly, No. 15 (Galβ1-3(NeuAcα2-6)GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Gal-PA) and No. 16 (Galβ1-3(NeuAcα2-6) (Fucα1-4)GlcNAcβ1-3Gal-PA) might be derived from disialosylated Lewis C (NeuAcα2-3Galβ1-3(NeuAcα2-6)GlcNAc-R) and disialosyl Figure 4 . Comparison of the levels of 17 sialylated marker candidate glycans between sera from gastric cancer patients, pancreatic cancer patients and normal controls The peak area in the extracted ion chromatogram (XIC) of each SRM transition was measured. (A-Q) The levels of 17 candidate glycans in sera from 11 gastric cancer patients (G1-G11), 9 pancreatic cancer patients (P1-P9) and 10 normal controls (N, in graphs only 10 cases out of 20 cases). The levels of candidate markers from the sera of gastric cancer patients (G), pancreatic cancer patients (P) and normal controls (N) are indicated by a gray, black and white bar, respectively. For conciseness, only odd numbered cases are shown in each figure. The mass values (Q1 mass), estimated structure and candidate number (Nos. 1-17), which were all shown in Table II and Figure 3 , are presented in each graph.
Lewis A (NeuAcα2-3Galβ1-3(NeuAcα2-6)(Fucα1-4)GlcNAc-R) determinants, respectively. We had originally predicted that oligosaccharides having a α2,6-sialylated type1 LacNAc structure (Galβ1-3(NeuAcα2-6)GlcNAc-R), and core1 and core3 oligosaccharides having α2,6-sialylated GalNAc at the reducing terminal ends (R 1 -(NeuAcα2-6)GalNAc-R 2 ), would be potential tumor marker candidates. Indeed, among the 17 candidates, Nos. 15, 16 and 17 have the former structure, and Nos. 2, 3, 4, 8, 12, 13 and 14 have the latter structure (core1; Nos. 8, 12, 13 and 14 and core3; Nos. 2, 3 and 4). In addition to these predicted candidates, we also identified eight oligosaccharides having Sd a /CAD antigens as tumor marker candidates. The levels of most of these Sd a /CAD antigens were markedly increased in the sera of some cancer patients (Figure 4 ). These candidates had various backbone structures, including core1, core2 and core3 structures, and Sd a /CAD antigens were linked by both a type1 and type2
LacNAc moiety. Synthesis of the Sd a /CAD structure, transfer of a GalNAc residue via a β1,4-linkage to a NeuAcα2-3Gal moiety, was mediated by the B4GALNT2 enzyme (Montiel et al. 2003) . The Sd a / CAD-β1,4-GalNAc-transferase activity was found in human normal large intestine and kidney (Piller et al. 1986; Malagolini et al. 1989 ). It appears unlikely that the reason for the elevation of Sd a /CAD Figure 4 . Continued antigens in sera of cancer patients was up-regulation of β1,4-GalNAc-transferase activity in cancerous tissues. In colorectal carcinoma, it was reported that its transferase activity was reduced when compared to that of the normal mucosa surrounding the tumor (Malagolini et al. 1989) . In agreement of this previous report, our structural analyses revealed that Sd a /CAD antigen in the isolated colorectal cancerous tissue was present at lower levels compared with the normal colon surrounding tumor foci (unpublished result). Furthermore, down-regulated expression of B4GALNT2 by DNA methylation occurs in gastrointestinal cancer and colon cancer cell lines (Malagolini et al. 1989; Kawamura et al. 2008; Wang et al. 2008) . A possible reason for these observations might be accelerated release of Sd a /CAD antigen into the bloodstream from cancerous tissues rather than up-regulation in the synthesis of the antigens. Measurement of the levels of 17 candidates in sera from 20 cancer patients and 20 normal controls revealed that glycans possessing the same backbone or determinant showed very similar patterns, despite their structural diversity. In particular, except for STn (No. 1), the candidates were categorized into five groups as follows. (1) Candidates having core3 backbone structures, Nos. 2, 3, 4, 5 and 6, showed marked elevation in sera from two cancer patients (G2 and G8) ( Figure 4B-F) . (2) Candidates having a α2,6-sialylated type1 LacNAc structure, Nos. 15, 16 and 17, showed slightly increased levels in several gastric and pancreatic patients ( Figure 4G-I) . (3) Candidates having a short core1 basal structure with an Sd a /CAD determinant, Nos. 7 and 8, showed slightly increased levels in sera of only one case (P3) ( Figure 4J and K). (4) Candidates having a core1 structure with an extended type1 LacNAc unit, Nos. 11, 12, 13 and 14, showed marked elevation in P3 sera, and significantly increased levels in several other cancer patients ( Figure 4L-O) . (5) The remaining two candidates, comprising Sd a /CAD determinants linked to the core1 structure, with an extended type2 LacNAc unit and basal core2 structure, showed marked elevation in sera of G7, G8 and P3 ( Figure 4P and Q). Thus, multiple quantitative analysis performed in parallel with a representative of each marker group will assist in the diagnosis of cancer. Here, the same sera samples were used as in our previous sulfated glycan-focused study. Thus, the levels of 14 sulfated markers and 17 internally sialylated markers in the 40 sera samples were compared and the validity of using a combinational approach for internally sialylated candidates and sulfated candidates assessed. A previous study focusing on sulfated glycans demonstrated the levels of each tumor marker candidate from the sera of 40 cases exhibited various patterns (Tanaka-Okamoto et al. 2017) . However, it is noteworthy that the pattern of levels between internally sialylated and sulfated candidates are quite different. In particular, a marked elevation of many internally sialylated candidates compared to normal controls were observed in sera of G2, G8 or P3. However, contrary to internally sialylated candidates, the levels of sulfated candidates in sera of G2 and G8 were very low and comparable to the levels seen in normal controls. Conversely, in the sera of patients, P4 and P8, showing very high levels of several sulfated candidates, the levels of internally sialylated candidates were low. Taken together, our results suggest the complementary role that these distinct markers can play in the diagnosis of cancer and demonstrate the effectiveness of using multiple tumor markers for this purpose. Moreover, the multiple use of these candidates is feasible because SRM is suitable for multiplex assay platforms. Indeed, when conditions for the SRM assay are fully optimized, most of the sulfated and internally sialylated candidates can be quantified in a single assay. We are currently developing and testing this technology in our laboratory. Thus far, our experiments use hydrazine, a hazardous chemical, to release O-glycans from glycoproteins. In future, other chemical methods, for example LiOHcatalyzed β-elimination, might be employed for high-throughput screening (Yamada et al. 2007) .
In summary, glycomic analyses focusing on internally sialylated O-glycans enabled us to efficiently identify 17 novel marker candidates. The structures of these candidates were precisely analyzed and then quantified using the SRM assay. These analyses revealed that the candidates comprise oligosaccharides of various structures, including glycans having a α2,6-sialylated reducing terminal GalNAc, α2,6-sialylated type1 LacNAc structure, and Sd a /CAD determinant. Candidate glycans having a related glycan structure showed similar patterns of elevation. However, an assessment of the effectiveness of using multiple candidates for screening various cancers is required.
Materials and methods

Serum samples
Serum samples of patients with gastric cancer (n = 11, male 6, female 5, mean age 56.7 years) and pancreatic cancer (n = 9, male 6, female 3, mean age 57.9 years) were obtained from Osaka International Cancer Institute. The 20 cancer patients recruited in this study were the same as for our previous glycomics study, which focused on sulfated markers (Tanaka-Okamoto et al. 2017) . Furthermore, all the sera used in this and the previous study were the same samples stored in −80°C. Serum samples of normal controls (n = 20, male 13, female 7, mean age 59.4 years) were obtained from cancer-free healthy volunteers. This study was approved by the Local Ethics Committee of Osaka International Cancer Institute. Informed consent was obtained from each patient and volunteer.
Preparation of PA-glycans from human sera
Experimental procedures, such as preparation/separation of PAglycans, were performed as previously reported (Tanaka-Okamoto et al. 2016) . Briefly, lyophilized samples of 80 μl sera were treated with hydrazine at 60°C for 16 h to liberate O-and N-glycans from the glycoproteins, followed by re-N-acetylation with acetic anhydride in a saturated sodium bicarbonate solution as previously described (Yabu et al. 2014) . Reducing ends of the liberated O-and Nglycans were then labeled with a fluorophore, 2-aminopyridine, by reductive amination (Natsuka et al. 2011) . Excess reagents were subsequently removed by phenol/chloroform extraction and cation exchange chromatography. PA-glycans were further purified using a graphite carbon cartridge (GL-Pak carbograph 300 mg; GL Science Ltd, Tokyo, Japan) (Natsuka et al. 2011) . Finally, the eluted PA-glycans were lyophilized and dissolved in 160 μl water.
Separation of PA-glycans
PA-oligosaccharides were separated on a Shimadzu LC-20A HPLC system equipped with a Waters 2475 fluorescence detector. The following experimental procedures, including normal phase HPLC and reversed phase HPLC have been reported previously ). Normal phase HPLC was performed on a TSK gel Amide-80 column (0.2 mm I.D. × 25 cm; Tosoh, Tokyo, Japan). The molecular size of each PA-oligosaccharide is given in glucose units (Gu) based on the elution times of PA-isomaltooligosaccharides. Reversed phase HPLC was performed on a TSK gel ODS-80Ts column (0.2 mm I.D. × is given in glucose units based on the elution times of PAisomaltooligosaccharides. Thus, a given compound on these two columns provides a unique set of Gu (amide) and Gu (ODS) values, which correspond to coordinates on the 2D map. Weak anion exchange HPLC was performed at 30°C on a TSK gel DEAE-5PW column (0.75 mm I.D. × 7.5 cm; Tosoh) at a flow rate of 0.8 ml/min. The solvents used were (A) aqueous ammonia, pH 9.0, and (B) 1 M ammonium acetate buffer, pH 9.0. The column was equilibrated with 100% solvent A and, after sample injection, solvent A was held at 100% for 0.5 min. Next, the level of solvent B was linearly increased from 0 to 14% in 17.5 min and then to 100% in 12.5 min.
Glycosidase digestion
Dose-dependent specificity of α2,3-neuraminidase from S. typhimurium. When sialyl PA-oligosaccharides were digested with 2 U/ml of α2,3-neuraminidase from S. typhimurium (New England BioLabs Inc, Ipswich, MA) in 100 mM sodium acetate buffer, pH 5.5, for 2 h at 37°C, α2,3-neuraminidase specifically liberated sialic acid α2,3-linked to the terminal residue, but not sialic acid with a α2,6-linkage. However, under conditions using 10 U/ml for 16 h, even so-called α2,3-neuraminidase can hydrolyze sialic acid both α2,3-and α2,6-linked to the terminal residue, but not sialic acid linked to an internal residue (Korekane et al. 2007; Shida et al. 2009 ). The latter conditions were used in this experiment.
Other glycosidases for digestion of PA-oligosaccharides were used under the following conditions; 2 U/ml of α-neuraminidase from A. ureafaciens (Nacalai, Kyoto, Japan) in 100 mM sodium acetate buffer, pH 5.5, for 16 h at 37°C; 0.2 mU/ml of α1,3/4-fucosidase from Streptomyces sp. 142 (Takara Bio Inc, Shiga, Japan) in 100 mM sodium acetate buffer, pH 5.5, for 2 h at 37°C; 0.4 U/ml β1,4-galactosidase from Streptococcus pneumoniae (Prozyme, San Leandro, CA) in 100 mM sodium citrate buffer, pH 6.0, for 2 h at 37°C; 1.5 U/μl β1,3-galactosidase from Xanthomonas manihotis (New England BioLabs Inc) in 100 mM sodium acetate buffer, pH 5.5, for 16 h at 37°C; 0.2 mU/ml of lacto-N-biosidase from Streptomyces sp. 142. (Takara Bio Inc.) in 100 mM sodium acetate buffer, pH 5.5, for 2 h at 37°C; 1 U/ml of β-N-acetylhexosaminidase from human placenta (Sigma-Aldrich, St Louis, MO) in 100 mM sodium citrate buffer, pH 4.3 for 16 h at 37°C.
Synthesis of Sd a /CAD glycans by glycosyltransferases
Crypts from human normal colon were sonicated in ice-cold 20 mM HEPES buffer (pH 7.4), 1% Triton X-100 for 3 min. Upon centrifugation at 12,000 × g for 10 min, the supernatants were used as sources of β1,4-GalNAc transferase. Each acceptor substrate was reacted in 50 mM MES buffer (pH 6.2), 10 mM MnCl 2 , 5 mM ATP, 0.1% Triton X-100, 2 mM UDP-GalNAc and 1 μl of enzyme source. Rat recombinant α2,3-(N)-sialyltransferase from Spodoptera frugiperda (CALBIOCHEM) was incubated in 100 mM cacodylate buffer (pH 6.5), 10 mM MnCl 2 , 0.45% Triton X-100, 5 mM CMP-sialic acid and acceptor substrate.
LC-MS/MS with full scan MS/MS acquisition
PA-oligosaccharides were analyzed by nano-LC/ESI MS/MS according to our previously reported procedures (Korekane et al. 2007) . HPLC was performed as described below in the LC-SRM/MS section. MS analyses were carried out using a LCQ ion trap mass spectrometer (Thermo Finnigan, San Jose, CA). In the LCQ method file, the LCQ was set to acquire a full MS scan between 400 and 2000 m/z followed by MS/MS scans in a data-dependent manner.
LC-SRM/MS
All samples, which were subfractionated by DEAE, normal phase HPLC and reversed phase HPLC in qualitative analyses, were analyzed by nano-LC-SRM/MS on a 4500 Q Trap hybrid triple quadrupole/linear ion trap mass spectrometer (Applied Biosystems, Framingham, MA) equipped with a nanoESI device (AMR, Inc., Tokyo, Japan) connected to a Paradigm MS4 μHPLC system (Michrom BioResources Inc., Auburn, CA). Reversed phase HPLC was performed at room temperature on a Magic C18 column (5 μm, 0.2 mm I.D. × 50 mm; Michrom BioResources) with a FortisTip capillary needle (AMR, Inc.) at a flow rate of 2 μl/min. The solvents used were (A) 5 mM acetic acid titrated to pH 6.0 with triethylamine, and (B) 50% (v/v) acetonitrile.
The column was pre-equilibrated with solvent A, and 3 minutes after injection of sample, solvent B was increased to 100% over 1 min and then held at 100% for 10 min. Data acquisition was performed with an ion spray voltage of 2200 curtain gas of 20 p.s.i., nebulizer gas of 15 p.s.i., an interface heater temperature of 150°C and dwell time of 50 ms. Two collision energies of 40 and 50 V or 50 and 60 V, declustering potential of 140 V, and collision cell exit potential of 15 V, were used for all SRM transitions. Two SRM transitions were monitored and acquired at low resolution both in the first and third quadrupoles (Q1 and Q3). SRM data acquired on the 4500 QTRAP were analyzed by MultiQuant v2.1.1 (Applied Biosystems). Integration settings included a smoothing width of one point and a peak splitting factor of 2. The more abundant transition of the two transitions was selected as the quantifier transition to be used in quantitative analyses. The peak area in the extracted ion chromatogram (XIC) of each SRM transition was measured. Based on the observation of signal-to-noise ratio of XIC corresponding to transitions monitored for candidate PA-glycans, we used an intensity of 500 as the LOQ (limit of quantification).
